3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
12
Lung Neoplasms
12
Brain Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
7
Breast Neoplasms
7
Gliosarcoma
6
Glioblastoma
6
Salivary Gland Neoplasms
5
Rectal Neoplasms
5
Glioma
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Astrocytoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Solid Tumors
4
Esophageal Neoplasms
4
Tongue Neoplasms
3
Prostatic Neoplasms
3
Oligodendroglioma
3
Lymphoma
3
Gallbladder Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Hepatocellular
3
Bile Duct Neoplasms
3
Advanced Cancers
3
Advanced Cancer
3
Interventions
Cisplatin
21
Etoposide
20
Carboplatin
20
Topotecan
13
pembrolizumab
12
durvalumab
11
Paclitaxel
10
Irinotecan
9
Nivolumab
7
Gemcitabine
7
tremelimumab
6
atezolizumab
6
Radiotherapy
6
Docetaxel
6
Pemetrexed
5
Ipilimumab
5
Cyclophosphamide
5
rovalpituzumab tesirine
4
budigalimab
4
Specimen Handling
4
Injections
4
Doxorubicin
4
Bortezomib
4
130-nm albumin-bound paclitaxel
4
venetoclax
3
talazoparib
3
olaparib
3
fludarabine
3
etoposide phosphate
3
Platinum
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Small Cell Lung Carcinoma
×
Erlotinib Hydrochloride
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled